Indeed, PD-L1 is a favorable target molecule for cancer immunotherapy and PD-L1-expressing malignant cells were killed by PD-L1-specific CD8+ CTLs in a PD-L1-dependent manner [24, 25]. The gene discussed is CD274; the disease is cancer.